profile image for Dr Nathalie Lavignac

Dr Nathalie Lavignac

Lecturer in Pharmaceutical Nanotechnology

Medway School of Pharmacy


Dr Nathalie Lavignac graduated from Bordeaux I University (France) in 1996 and discovered her interest for Drug Delivery Systems during her Master research project. She then worked for Biovector Therapeutics a biotechnology laboratory that developed non-viral vectors for the delivery of antigens. In 1998, Nathalie moved to the United Kingdom and completed her PhD in 2002 on molecularly imprinted polymers at Cardiff University, Welsh School of Pharmacy. After her PhD, she joined ML Laboratories (previously Cobra Therapeutics), a pharmaceutical company in Keele (UK), where she worked in the field of non-viral gene delivery. In 2003, Nathalie returned to The Welsh School of Pharmacy in the Centre for Polymer Therapeutics and developed polymers for the delivery of biomacromolecules. She then moved back to France and worked at the CNRS in Paris, developing conducting polymers. In October 2006, Nathalie was appointed as a lecturer in Pharmaceutical Nanotechnology at the Medway School of Pharmacy.

back to top

Dr Lavignac research interests focus on the development of polymeric and peptidic nanocarriers to deliver drugs and macromolecular drugs acting on an intracellular therapeutic target. This requires adopting a multidisciplinary approach to project management and involves working at the interface of chemistry and biology, often considering any potential translational applications. Currently she's focusing on three different clinical areas: bacterial infections, oncology, and immunology.

A project will start with the synthesis and the physicochemical characterisation of a synthetic vector, polymer and/or peptide-based, which will be further used to promote the cellular delivery of selected drugs or biomacromolecules (e.g. proteins, DNA, siRNA). Using appropriate model cell lines, the group will assess the safety and capacity of these carriers to deliver the therapeutic agents using a non-targeted or targeted (i.e. cell specific) approach.

The following stage involves understanding the mechanism of action and intracellular trafficking of these nanocarriers and correlate their physicochemical properties with their biological activity, with the objective to design and develop new polymeric and peptidic vectors with improved efficiency.

See here for full information on PhD opportunities.

Received Funding

  • Kent Cancer Trust
  • Medway School of Pharmacy
  • University of Kent
back to top
  • D.R. Garcia and N. Lavignac (2016) Poly(amidoamine)-BSA conjugates synthesised by Michael addition reaction retained enzymatic activity: Polymer Chemistry, 7, 7223-7229. DOI: 10.1039/c6py01771a
  • J.N.L. Dubois and N. Lavignac (2015) Cationic poly(amidoamine) promote cytosolic delivery of bovine RNase A while maintaining its cellular toxicity. Journal of Material Chemistry B, 3, 6501-6508. DOI: 10.1039/c4tb02065k
  • J.N.L. Dubois and N. Lavignac (2014) Poly(amidoamine)s synthesis, characterisation and interaction with BSA. Polymer Chemistry, 5, 1586-1592. DOI: 10.1039/c3py01121f
  • Richardson, S. C. W.; Pattrick, N. G.; Lavignac, N.; Ferruti, P.; Duncan, R. (2010) Intracellular fate of bioresponsive poly(amidoamine)s in vitro and in vivo. Journal of Controlled Release, 142: 78-88.
  • Lavignac N. (2009) Synthesis of poly(amidoamine)s by microwave-assisted polymerisation, Journal of Pharmacy and Pharmacology, 61:S1-A4.
  • Khraund G.S., Dubois J. and Lavignac N. (2009) Synthesis and characterisation of a novel poly(amidoamine)s for use as a potential protein delivery system. Journal of Pharmacy and Pharmacology, 61:S1-A53.
  • Lavignac N., Nicholls J.L., Ferruti P. and Duncan R. (2009) Poly(amidoamine) conjugates containing doxorubicin bound via an acid-sensitive linker, Macromolecular Bioscience, 9: 480-487.
  • Lavignac N., Allender C. J. and Brain K. R. (2006) Concentration dependent atrazine–atrazine complex formation promotes selectivity in atrazine imprinted polymers. Bioscensors and Bioelectronics, 22: 138-144.
  • Lavignac N., Lazenby M., Franchini J., Ferruti P. and Duncan R. (2005) Synthesis and preliminary evaluation of poly(amidoamine)–melittin conjugates as endosomolytic polymers and/or potential anticancer therapeutics. International Journal of Pharmaceutics, 300:102-112.
  • Khayat, Z., Duncan, R., Lavignac, N., Griffiths, P. and Paul, A. (2004) Use of small-angle neutron scattering (SANS) and surface tension to better understand the mechanism of membrane and surfactant micelle interaction of endosomolytic polyamicloamines Journal of Pharmacy and Pharmacology, 56: S13-S14.
  • Lavignac N., Lazenby M., Franchini J., Ferruti P. and Duncan R (2004) Synthesis and endosomolytic properties of poly(amidoamine) block copolymers. Macromolecular Bioscience, 4:922-929.
  • Lavignac N., Allender C.J. and Brain K.R. (2004) 4-(3-aminopropylene)-7-nitrobenzofurazan: a new polymerisable monomer to develop homogeneous molecularly imprinted sorbent fluoroassay. Tetrahedron Letters, 45:3625-3627.
  • Lavignac N., Allender C.J. and Brain K.R. (2004) Current status of molecularly imprinted polymers as alternatives to antibodies in sorbent assays. Analitica Chimica Acta. 510:139-145.
back to top

Tel: +44 (0) 1634 202935
Fax: +44 (0) 1634 883927

Copyright © Medway School of Pharmacy
Last Updated 04/03/2019